Novo Nordisk (NYSE: NVO) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept.

BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Antisemitic assaults on visiting Israeli soccer fans, and incendiary chants and attacks by some Israelis: Here’s what we know so far about the violence in Amsterdam last week. By Jim ...

Nov. 11, 2024 — Why is the expansion of our Universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves ...

The reesults come less than two months after Novo entered into a multi-year partnership worth $600m with NanoVation Therapeutics to advance genetic medicines for cardiometabolic and rare diseases. The ...

Nov. 1, 2024 — Microplastics have been steadily increasing in freshwater environments for decades and are directly tied to rising global plastic production since the 1950s, according to a new ...

Why are the two often so disconnected? And what role can technology play in integrating them? A new CMS accountable care program aims to drive progress, and one expert explains what it means for ...

MarketBeat Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines ...

The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...